Cardiol Therapeutics Expands MAVERIC Trial with New Clinical Centers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2026
0mins
Source: Newsfilter
- Patient Recruitment Progress: The MAVERIC trial has surpassed 75% patient enrollment, up from over 50% in early January, with target recruitment expected by the end of Q2 2026, potentially extending into Q3 to accommodate additional clinical sites, thereby accelerating clinical advancements in heart disease treatment.
- Clinical Center Expansion: The planned activation of up to seven additional clinical centers in the U.S. reflects strong interest from leading medical institutions in the MAVERIC trial, which not only enhances the credibility of the research but may also provide richer clinical data to support CardiolRx™'s New Drug Application with the FDA.
- Trial Design and FDA Alignment: The MAVERIC trial has been designed in alignment with the FDA, ensuring scientific rigor and effectiveness, aiming to enroll approximately 110 patients to further validate CardiolRx™'s efficacy in preventing recurrent pericarditis, which holds significant clinical implications.
- Clinical Data Foundation: MAVERIC builds on positive Phase II data, demonstrating that CardiolRx™ can rapidly and sustainably reduce pericarditis pain and inflammation while significantly decreasing recurrence rates, providing strong clinical support for its application in heart disease treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRDL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRDL
Wall Street analysts forecast CRDL stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.280
Low
8.00
Averages
8.50
High
9.00
Current: 1.280
Low
8.00
Averages
8.50
High
9.00
About CRDL
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cardiol Therapeutics to Participate in Investor Conference
- Investor Conference Participation: Cardiol Therapeutics will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, in New York, showcasing its latest advancements in heart disease treatment, which is expected to attract investor interest.
- Clinical Trial Progress: The company's lead small-molecule drug candidate, CardiolRx™, is undergoing a pivotal Phase III trial for recurrent pericarditis, with FDA granting Orphan Drug Designation, indicating its potential in heart disease treatment and possibly enhancing the company's market position in the biopharmaceutical sector.
- New Drug Development: Cardiol is also developing CRD-38, a novel subcutaneous formulation aimed at treating inflammatory heart disease, including heart failure, which is a leading cause of death and hospitalization in developed countries, with associated healthcare costs exceeding $30 billion annually, highlighting significant market demand.
- Forward-Looking Information Statement: The press release contains forward-looking information, emphasizing the company's focus on heart disease treatment and future clinical research plans, urging investors to approach this information cautiously to avoid over-reliance on future performance expectations.
See More
Cardiol Therapeutics Advances Heart Disease Treatment with CardiolRx™
- Clinical Study Results: Cardiol Therapeutics' Phase II study results indicate that CardiolRx™ significantly reduces pericarditis pain and inflammation in patients with a high baseline disease burden, supporting its further development in the Phase III MAVERIC trial.
- Safety and Tolerability: The study demonstrates that CardiolRx™ has a favorable safety and tolerability profile, significantly reducing the number of pericarditis episodes per year, highlighting its potential as a non-immunosuppressive therapy to meet urgent patient needs.
- Trial Progress: The MAVERIC trial has surpassed 75% enrollment, establishing a solid foundation for the clinical application of CardiolRx™, which is expected to provide more effective treatment options for heart disease patients.
- Independent Validation: The upcoming publication in JAHA provides independent validation of the Phase II study results, further emphasizing the significance of CardiolRx™ in heart disease treatment and its potential to transform existing therapeutic approaches.
See More
Cardiol Expands MAVERIC Trial Centers in U.S.
- Trial Expansion: Cardiol Therapeutics announced the expansion of its pivotal Phase III MAVERIC trial in the U.S. with plans to activate up to seven additional clinical centers, reflecting strong interest in its therapeutic approach and aiming for target recruitment by Q2 2026.
- Patient Recruitment Progress: Enrollment in the MAVERIC trial has surpassed 75%, indicating the company's potential in heart disease treatment, particularly in recurrent pericarditis, which could significantly enhance patient quality of life.
- Clinical Data Support: The MAVERIC trial builds on the Phase II MAvERIC study, which demonstrated that CardiolRx™ rapidly and sustainably reduces pericarditis pain and inflammation, supporting its potential as a non-immunosuppressive oral therapy.
- FDA Designation: CardiolRx™ has received Orphan Drug Designation from the U.S. FDA, further strengthening its market competitiveness in heart disease treatment and expected to provide robust data support for future drug approval applications.
See More
Cardiol Therapeutics Expands MAVERIC Trial with New Clinical Centers
- Patient Recruitment Progress: The MAVERIC trial has surpassed 75% patient enrollment, up from over 50% in early January, with target recruitment expected by the end of Q2 2026, potentially extending into Q3 to accommodate additional clinical sites, thereby accelerating clinical advancements in heart disease treatment.
- Clinical Center Expansion: The planned activation of up to seven additional clinical centers in the U.S. reflects strong interest from leading medical institutions in the MAVERIC trial, which not only enhances the credibility of the research but may also provide richer clinical data to support CardiolRx™'s New Drug Application with the FDA.
- Trial Design and FDA Alignment: The MAVERIC trial has been designed in alignment with the FDA, ensuring scientific rigor and effectiveness, aiming to enroll approximately 110 patients to further validate CardiolRx™'s efficacy in preventing recurrent pericarditis, which holds significant clinical implications.
- Clinical Data Foundation: MAVERIC builds on positive Phase II data, demonstrating that CardiolRx™ can rapidly and sustainably reduce pericarditis pain and inflammation while significantly decreasing recurrence rates, providing strong clinical support for its application in heart disease treatment.
See More
Cardiol Therapeutics (CRDL) Raises $13.5M Through Bought-Deal Private Placement at $1.30/Unit
- Funding Size: Cardiol Therapeutics has entered into a bought-deal agreement with Canaccord Genuity to issue 10.38 million units at $1.30 each, successfully raising $13.5 million, thereby strengthening its financial position for future growth.
- Over-Allotment Option: The underwriter has the option to purchase an additional 10% of the units, potentially increasing proceeds by $1.35 million, providing the company with further funding flexibility.
- Unit Composition: Each unit consists of one Class A common share and one-half of a common share purchase warrant, which can be exercised at $1.75 per share for 24 months post-issuance, enhancing potential returns for investors.
- Use of Proceeds: The proceeds from this financing will be used to advance research and clinical development programs, as well as for working capital and general corporate purposes, reflecting the company's strategic planning for future growth.
See More
MongoDB Shares Surge Over 22%; Check Out 20 Stocks Making Moves in Premarket Trading
MongoDB's Strong Performance: MongoDB Inc. shares surged 22.8% in pre-market trading after reporting third-quarter revenue of $628.31 million, exceeding analyst expectations, and raising its FY26 guidance.
Other Notable Gainers: Taoping Inc. saw a 64.5% increase after announcing an acquisition, while Fitell Corp. rose 37.6% following a repurchase program announcement.
Significant Losers: Janux Therapeutics Inc. experienced a 39.3% drop in pre-market trading after releasing updated interim data, while American Bitcoin Corp. fell 17% after a previous decline.
Market Overview: The article highlights various stocks moving in pre-market trading, showcasing both significant gainers and losers, reflecting market volatility.
See More
Cardiol Therapeutics to Participate in Investor Conference
- Investor Conference Participation: Cardiol Therapeutics will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, in New York, showcasing its latest advancements in heart disease treatment, which is expected to attract investor interest.
- Clinical Trial Progress: The company's lead small-molecule drug candidate, CardiolRx™, is undergoing a pivotal Phase III trial for recurrent pericarditis, with FDA granting Orphan Drug Designation, indicating its potential in heart disease treatment and possibly enhancing the company's market position in the biopharmaceutical sector.
- New Drug Development: Cardiol is also developing CRD-38, a novel subcutaneous formulation aimed at treating inflammatory heart disease, including heart failure, which is a leading cause of death and hospitalization in developed countries, with associated healthcare costs exceeding $30 billion annually, highlighting significant market demand.
- Forward-Looking Information Statement: The press release contains forward-looking information, emphasizing the company's focus on heart disease treatment and future clinical research plans, urging investors to approach this information cautiously to avoid over-reliance on future performance expectations.
See More
Cardiol Therapeutics Advances Heart Disease Treatment with CardiolRx™
- Clinical Study Results: Cardiol Therapeutics' Phase II study results indicate that CardiolRx™ significantly reduces pericarditis pain and inflammation in patients with a high baseline disease burden, supporting its further development in the Phase III MAVERIC trial.
- Safety and Tolerability: The study demonstrates that CardiolRx™ has a favorable safety and tolerability profile, significantly reducing the number of pericarditis episodes per year, highlighting its potential as a non-immunosuppressive therapy to meet urgent patient needs.
- Trial Progress: The MAVERIC trial has surpassed 75% enrollment, establishing a solid foundation for the clinical application of CardiolRx™, which is expected to provide more effective treatment options for heart disease patients.
- Independent Validation: The upcoming publication in JAHA provides independent validation of the Phase II study results, further emphasizing the significance of CardiolRx™ in heart disease treatment and its potential to transform existing therapeutic approaches.
See More
Cardiol Expands MAVERIC Trial Centers in U.S.
- Trial Expansion: Cardiol Therapeutics announced the expansion of its pivotal Phase III MAVERIC trial in the U.S. with plans to activate up to seven additional clinical centers, reflecting strong interest in its therapeutic approach and aiming for target recruitment by Q2 2026.
- Patient Recruitment Progress: Enrollment in the MAVERIC trial has surpassed 75%, indicating the company's potential in heart disease treatment, particularly in recurrent pericarditis, which could significantly enhance patient quality of life.
- Clinical Data Support: The MAVERIC trial builds on the Phase II MAvERIC study, which demonstrated that CardiolRx™ rapidly and sustainably reduces pericarditis pain and inflammation, supporting its potential as a non-immunosuppressive oral therapy.
- FDA Designation: CardiolRx™ has received Orphan Drug Designation from the U.S. FDA, further strengthening its market competitiveness in heart disease treatment and expected to provide robust data support for future drug approval applications.
See More
Cardiol Therapeutics Expands MAVERIC Trial with New Clinical Centers
- Patient Recruitment Progress: The MAVERIC trial has surpassed 75% patient enrollment, up from over 50% in early January, with target recruitment expected by the end of Q2 2026, potentially extending into Q3 to accommodate additional clinical sites, thereby accelerating clinical advancements in heart disease treatment.
- Clinical Center Expansion: The planned activation of up to seven additional clinical centers in the U.S. reflects strong interest from leading medical institutions in the MAVERIC trial, which not only enhances the credibility of the research but may also provide richer clinical data to support CardiolRx™'s New Drug Application with the FDA.
- Trial Design and FDA Alignment: The MAVERIC trial has been designed in alignment with the FDA, ensuring scientific rigor and effectiveness, aiming to enroll approximately 110 patients to further validate CardiolRx™'s efficacy in preventing recurrent pericarditis, which holds significant clinical implications.
- Clinical Data Foundation: MAVERIC builds on positive Phase II data, demonstrating that CardiolRx™ can rapidly and sustainably reduce pericarditis pain and inflammation while significantly decreasing recurrence rates, providing strong clinical support for its application in heart disease treatment.
See More
Cardiol Therapeutics (CRDL) Raises $13.5M Through Bought-Deal Private Placement at $1.30/Unit
- Funding Size: Cardiol Therapeutics has entered into a bought-deal agreement with Canaccord Genuity to issue 10.38 million units at $1.30 each, successfully raising $13.5 million, thereby strengthening its financial position for future growth.
- Over-Allotment Option: The underwriter has the option to purchase an additional 10% of the units, potentially increasing proceeds by $1.35 million, providing the company with further funding flexibility.
- Unit Composition: Each unit consists of one Class A common share and one-half of a common share purchase warrant, which can be exercised at $1.75 per share for 24 months post-issuance, enhancing potential returns for investors.
- Use of Proceeds: The proceeds from this financing will be used to advance research and clinical development programs, as well as for working capital and general corporate purposes, reflecting the company's strategic planning for future growth.
See More
MongoDB Shares Surge Over 22%; Check Out 20 Stocks Making Moves in Premarket Trading
MongoDB's Strong Performance: MongoDB Inc. shares surged 22.8% in pre-market trading after reporting third-quarter revenue of $628.31 million, exceeding analyst expectations, and raising its FY26 guidance.
Other Notable Gainers: Taoping Inc. saw a 64.5% increase after announcing an acquisition, while Fitell Corp. rose 37.6% following a repurchase program announcement.
Significant Losers: Janux Therapeutics Inc. experienced a 39.3% drop in pre-market trading after releasing updated interim data, while American Bitcoin Corp. fell 17% after a previous decline.
Market Overview: The article highlights various stocks moving in pre-market trading, showcasing both significant gainers and losers, reflecting market volatility.
See More
